28 Apr 2022 Eminetra Australia Positive test results for Alzheimer’s drug Xanamem
28 Apr 2022 TechInvest Actinogen announces positive XanaMIA Part A trial
28 Apr 2022 Aged Care News Millions could benefit after breakthrough Alzheimer’s treatment trial by Aussie biotech
28 Apr 2022 Hospital and Healthcare Positive trial results for Alzheimer’s drug Xanamem
27 Apr 2022 Biotech Daily Actinogen XanaMIA Phase 1B Part A Trial Meets Endpoints
27 Apr 2022 The Sentiment New trial results from Actinogen hold promise for Alzheimer’s treatment
27 Apr 2022 The Market Herald Actinogen Medical (ASX:ACW) reports positive XanaMIA Part A trial topline results
27 Apr 2022 Kalkine Media Actinogen gets upbeat results from Xanamem trial for Alzheimer’s treatment
27 Apr 2022 Mirage News Millions worldwide could benefit after breakthrough trial in treatment for Alzheimer’s
27 Apr 2022 Actinogen Media Release: Millions worldwide could benefit after a breakthrough trial in the treatment for Alzheimer’s by Aussie biotech Actinogen
11 Feb 2022 The Market Herald Actinogen Medical (ASX:ACW) advances Alzheimer’s treatment
09 Feb 2022 The Sentiment Actinogen appoints leading researchers to conduct Phase 2 trials for treatment of Fragile X Syndrome
09 Feb 2022 The Market Herald Actinogen Medical (ASX:ACW) locks in trial manager for FXS phase-two study
09 Feb 2022 Biotech Daily Worldwide To Manage Xanamem Fragile X Trial
22 Dec 2021 Stockhead Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021. Best performing ASX biotechs in 2021.
07 Dec 2021 The Market Herald Actinogen Medical (ASX:ACW) partners with Oxford University
07 Dec 2021 Stockhead ASX Health Stocks: Neuren stock price up 100pc on positive Phase 3 results In other ASX health news this morning: Actinogen Medical (ASX:ACW) has announced strategic collaboration with Oxford University researchers A
29 Nov 2021 The Sentiment Better than a sudoku: could this drug be the key to preventing Alzheimer’s?
15 Jul 2021 Stockhead These two ASX brain health stocks, boosted by FDA’s approval of Adulhelm, are kicking off clinical trials
15 Jul 2021 Biotech Daily Actinogen Enrols 1st XanaMIA Trial Patient
15 Jul 2021 The Market Herald Actinogen Medical (ASX:ACW) enrols first patient in Alzheimer’s Disease trial
15 Jul 2021 Monex Trading the World Here’s why the Actinogen (ASX:ACW) share price is rocketing 13% today
09 Jul 2021 Fragile X News Today FDA OKs Phase 2 Trial Design for Xanamem
23 Jun 2021 Stockhead Actinogen Medical gets a further boost from supportive FDA advice, shares up 7-fold in 2021
22 Jun 2021 The Motley Fool Here’s why the Actinogen Medical (ASX:ACW) share price is up 20%
21 Jun 2021 Biotech Daily Actinogen Appoints 2 CROs, Cogstate For XanaMIA
21 Jun 2021 The Market Herald Actinogen Medical (ASX:ACW) takes next step towards cortisol study
21 Jun 2021 Stockhead Dr Boreham’s Crucible: Time to make a song and dance about Actinogen (ASX:ACW)?
18 Jun 2021 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
16 Jun 2021 The Motley Fool Why is the Actinogen (ASX:ACW) share price up 414% in 3 months?
10 Jun 2021 Stockhead Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
10 Jun 2021 Share Cafe Alzheimer’s Decision Sends Positive Message to Aussie Biotechs
08 Jun 2021 Stockhead FDA’s landmark approval of Biogen’s Alzheimer’s drug sends Cogstate up 60 per cent
04 Jun 2021 Stockhead Actinogen to progress Alzheimer’s study
02 Jun 2021 The Market Herald Actinogen Medical (ASX:ACW) granted ethics committee approval for Alzheimers study
02 Jun 2021 Biotech Daily Actinogen: Part-A Xanamia Xanamem Cognition Trial Approved
22 Apr 2021 Biotech Daily Actinogen Plans Three Phase II Cognition Trials For 2022
15 Apr 2021 The Motley Fool Actinogen (ASX:ACW) share price surges 23% today, 165% this year
15 Mar 2021 Biotech Daily Actinogen Appoints Dr Steven Gourlay CEO On $400k
15 Mar 2021 The Market Herald Actinogen Medical (ASX:ACW) appoints new CEO
11 Feb 2021 Biotech Daily Actinogen Shortfall Raises $3.55m – Total $10.9m
05 Feb 2021 The Market Herald Actinogen (ASX:ACW) nabs FDA designation for Fragile X treatment
20 Nov 2020 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
13 Nov 2020 Biotech Daily Actinogen Rights Raise $1.4m Of Hoped-For $4.9m – Total $7.4m
09 Nov 2020 The Market Herald Actinogen Medical (ASX:ACW) files new patent applications
09 Nov 2020 The Motley Fool Actinogen Medical (ASX:ACW) share price jumps on patent news
09 Nov 2020 Fintech Inshorts Actinogen Medical: Files New Patent Applications
23 Oct 2020 Fragile X News Today Phase 2 Trial Planned for Xanamem, Oral Treatment for Fragile X
19 Oct 2020 Bioshares Edition 865: Actinogen Sets Clear Direction with Capital Raise
15 Oct 2020 Biotech Daily Actinogen Up-To $11m Capital Raising For Xanamem Trials
15 Oct 2020 The Market Herald Actinogen Medical (ASX:ACW) to begin two clinical trials, $10.9M capital raise
15 Oct 2020 Stockhead Actinogen reveals its next clinical trial plans
15 Oct 2020 Investing.com BRIEF-Actinogen Medical Announces Two Clinical Trials
13 Oct 2020 Financial Review Bell Potter raising for Alzheimer’s drug hopeful Actinogen
13 Oct 2020 The Age As it happened: ASX misses 6200, but gains 1% 11.13am Actinogen in trading halt ahead of raise announcement
13 Oct 2020 The Market Herald Actinogen Medical (ASX:ACW) flags future capital raise
29 Sep 2020 Biotech Dispatch Actinogen Medical announces the appointment of new CFO
17 Jul 2020 Innovation Intelligence Alzheimer’s treatment could be worth $10bn annually
25 Nov 2019 ABC News Dementia and Alzheimer’s disease trials giving patients hope of a better life
25 Nov 2019 The New Daily Dementia and Alzheimer’s disease trials giving patients hope of a better life
27 Oct 2019 The Bull.com.au A Biotech Conference for Stock-Pickers
24 Oct 2019 The Market Herald Actinogen Medical down 9.3pc despite tax rebate
07 Oct 2019 Bioshares Edition 812: Actinogen Gets Early Positive Data in Healthy Older Adults with Higher Dose of Xanamem
06 Oct 2019 Stockhead Dr Boreham’s Crucible: Actinogen on the mend after a near-death experience
04 Oct 2019 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
02 Oct 2019 Finfeed Actinogen’s shares surge 460% after Xanamem success
01 Oct 2019 Biotech Daily Actinogen: ‘Xanamem Improves Cognition In Healthy Volunteers’
01 Oct 2019 Small Caps Actinogen Medical announces ‘breakthrough’study results for Alzheimer’s drug Xanamem
01 Oct 2019 Stockhead Health: Actinogen recovers some hope from Xanamem wreckage
01 Oct 2019 Pharmaceutical Daily News Actinogen Medical pleased with positive efficacy data for Xanamem in Alzheimer’s patients
01 Oct 2019 Motley Fool Why Actinogen Medical shares climbed 466% on excitement over an Alzheimer’s treatment
29 Jun 2019 Finfeed Cortisol inhibition – a potential new approach to treating Alzheimer’s disease
03 Jun 2019 Bioshares Edition 794: Actinogen – Update on Higher Dose Safety Study
13 May 2019 Bioshares Edition 791: Actinogen – Phase II Study Dose Too Low
07 May 2019 The Motley Fool Actinogen Medical share price crashes 67% lower on Alzheimer’s study results
07 May 2019 Investing.com BRIEF-Actinogen Medical Updates On Phase II Alzheimer’s Disease Trial Results
07 May 2019 Kalkine Media Actinogen Medical Released Alzheimer’s Disease Trial
07 May 2019 Small Caps Actinogen Medical phase two Alzheimer’s clinical trial disappoints
07 May 2019 Biotech Dispatch XanADu trial disappoints for Actinogen Medical
07 May 2019 Stockhead Health: Actinogen’s Alzheimer’s treatment comes up short, stock crashes 70pc
07 May 2019 news.com.au Actinogen shares crash after drug trial
07 May 2019 Alzheimer Europe Actinogen Medical announces results from its Phase II clinical trial XanADu in AD
09 Apr 2019 News.com.au Aussie pill could hold cure for Alzheimer’s
04 Apr 2019 Biotech Dispatch Actinogen appoints new director
25 Mar 2019 Bioshares A Local Investment Perspective
01 Mar 2019 Neuro Central International Women’s Day: A day in the life of Tamara Miller
30 Jan 2019 BioWorld Australian’s Actinogen tackles Alzheimer’s disease by inhibiting excess cortisol in the brain
04 Jan 2019 Stockhead Actinogen in the Stockhead 1000+ club – one of only six small cap healthcare companies to grow more than 1000 percent over the last decade
18 Dec 2018 Cognitive Vitality Does stress worsen cognitive functions?
08 Dec 2018 The West Australian Trial drug offers hope for Alzheimer’s treatment
27 Nov 2018 Biotech Dispatch Final patient enrolled in Actinogen’s XanADu trial
26 Nov 2018 Business Wire Final Patient Enrolled in Landmark Alzheimer’s Treatment Trial Targeting Stress Hormone Cortisol
20 Nov 2018 Australian Financial Review (AFR) Developing potential Alzheimer’s treatment Investors eye new drug’s possibilities
01 Nov 2018 BioPharma Dealmakers Targeting cortisol to treat Alzheimer’s disease and cognitive impairment
01 Nov 2018 Proactive Investors Actinogen moves to next stage of Alzheimer’s treatment trials
05 Sep 2018 Stockhead Why Actinogen’s progress is good news for Alzheimer’s patients and investors
16 Aug 2018 Pharma In Focus Australian Alzheimer drug progresses
15 Aug 2018 Stockhead Actinogen Hits Enrolment Milestone for Alzheimer’s Treatment Clinical Trial
15 Aug 2018 LabOnline Patient enrolment for Alzheimer’s trial close to completion
09 Aug 2018 Biotech Dispatch Recognition for Actinogen Medical advisor

Back
to top